Loading...
•
Dec 31, 2024
Ironwood Pharmaceuticals Q4 2024 Earnings Report
Reported fourth quarter and full year 2024 results, achieving 2024 financial guidance and advancing apraglutide through regulatory submission.
Key Takeaways
Ironwood Pharmaceuticals reported its fourth quarter and full year 2024 results, highlighting progress with apraglutide and continued LINZESS demand growth. The company is preparing for the potential launch of apraglutide and streamlining operations for long-term value creation.
Reported positive data from open-label extension study demonstrating an increased number of patients on apraglutide achieving enteral autonomy over time.
Initiated rolling NDA submission for apraglutide, on track to be completed in Q3 2025.
LINZESS® (Iinaclotide) EUTRx prescription demand growth of 11% for full-year 2024 year-over-year.
2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million.
Forward Guidance
Ironwood anticipates total revenue between $800 and $850 million in 2025. Expects high single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...